Is BIOVF or DGRO a better dividend investment in 2026?

BIOVF currently yields 5.02% with a 5% 5-year dividend growth rate. DGRO yields 2.10% with 9.5% growth. The better choice depends on your goal: BIOVF offers higher current income.

What is the dividend yield difference between BIOVF and DGRO?

BIOVF has a forward dividend yield of 5.02% ($2.00/share annually). DGRO yields 2.10% ($1.47/share annually). The yield gap is 2.92 percentage points.

Home › Compare › BIOVF vs DGRO

BIOVF vs DGRO: Dividend Comparison 2026

BIOVF yields 5.02% · DGRO yields 2.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 DGRO wins by $3.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

BIOVF

● Live price

5.02%

Share price

$39.87

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.8K

Annual income

$691.40

Full BIOVF calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.10%

Share price

$70.18

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$235.38

Full DGRO calculator →

Portfolio growth — BIOVF vs DGRO

📍 DGRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BIOVF	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BIOVF + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BIOVF pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOVF

Annual income on $10K today (after 15% tax)

$426.38/yr

After 10yr DRIP, annual income (after tax)

$587.69/yr

DGRO

Annual income on $10K today (after 15% tax)

$178.14/yr

After 10yr DRIP, annual income (after tax)

$200.07/yr

At 15% tax rate, BIOVF beats the other by $387.62/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOVF + DGRO for your $10,000?

BIOVF: 50%DGRO: 50%

100% DGRO50/50100% BIOVF

Portfolio after 10yr

$29.7K

Annual income

$463.39/yr

Blended yield

1.56%

📊

Analyst Conviction Gap

Where Wall Street is split right now

BIOVF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

3.7

Piotroski

6/9

DGRO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOVF buys

DGRO buys

No recent congressional trades found for BIOVF or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBIOVFDGRO

Forward yield	5.02% ✓	2.10%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$27.8K	$31.6K ✓
Annual income after 10y	$691.40 ✓	$235.38
Total dividends collected	$6.0K ✓	$2.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: BIOVF vs DGRO ($10,000, DRIP)

Year	BIOVF Portfolio	BIOVF Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$11,202	$501.63	$11,290	$209.57	$88.00 → DGRO
2	$12,511	$525.15	$12,722	$213.54	$211.00 → DGRO
3	$13,935	$548.15	$14,314	$217.18	$379.00 → DGRO
4	$15,481	$570.60	$16,080	$220.53	$599.00 → DGRO
5	$17,157	$592.44	$18,040	$223.59	$883.00 → DGRO
6	$18,972	$613.63	$20,215	$226.40	$1.2K → DGRO
7	$20,934	$634.14	$22,627	$228.96	$1.7K → DGRO
8	$23,053	$653.95	$25,302	$231.31	$2.2K → DGRO
9	$25,340	$673.04	$28,268	$233.44	$2.9K → DGRO
10	$27,805	$691.40	$31,557	$235.38	$3.8K → DGRO

BIOVF vs DGRO: Complete Analysis 2026

BIOVF — Stock

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Full BIOVF Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this BIOVF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOVF vs SCHD BIOVF vs JEPI BIOVF vs O BIOVF vs KO BIOVF vs MAIN BIOVF vs VIG BIOVF vs NOBL BIOVF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.